Related Experiment Video

Updated: May 2, 2026

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

1.1K

Novel agents for the treatment of pancreatic cancer

Gregory T Brennan1, Valerie Relias, Muhammad Wasif Saif

  • 1Department of Internal Medicine, University of Texas Southwestern Medical Center. Dallas, TX, USA. gregorybrennan@phhs.org.

JOP : Journal of the Pancreas
|March 13, 2014
PubMed

Insights

Novel treatments for metastatic pancreatic cancer show promise. Phase I/II trials presented immunotherapy, a MUC5AC antibody, and an HSP90 inhibitor, offering new hope for patients with this aggressive disease.

Area of Science:

  • Oncology
  • Gastrointestinal Cancers
  • Immunotherapy

Background:

  • Metastatic pancreatic cancer presents significant treatment challenges due to its aggressive nature and late-stage diagnosis.
  • There is a critical need for novel therapeutic strategies targeting new pathways to improve patient outcomes.

Framework:

  • The 2014 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium highlighted three innovative approaches in phase I/II trials.
  • These novel strategies aim to address the unmet needs in treating advanced pancreatic cancer.

Implementation:

  • GVAX vaccine combined with CRS-207 immunotherapy demonstrated extended survival in patients.
  • NEO-102, a monoclonal antibody targeting MUC5AC, exhibited positive activity and good tolerability.
  • Ganetespib, a heat shock protein 90 (HSP90) inhibitor, showed modest efficacy and favorable tolerability, suggesting potential combination use with standard chemotherapy.

Implications:

  • These findings represent promising advancements in the therapeutic landscape for metastatic pancreatic cancer.
  • Further investigation and development of these novel agents are warranted to improve treatment efficacy and patient survival.

More Related Videos

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.7K
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.7K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
820
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K